NIOX Group Plc (FRA:82C)

Market Cap	327.48M -2.4%
Revenue (ttm)	55.82M +24.9%
Net Income	8.02M -40.2%
EPS	0.02 -36.7%
Shares Out	n/a
PE Ratio	40.81
Forward PE	28.38
Dividend	0.02 (2.33%)
Ex-Dividend Date	May 21, 2026

Volume	n/a
Open	0.7500
Previous Close	0.7450
Day's Range	0.7500 - 0.7750
52-Week Range	0.6000 - 0.8850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2026

About NIOX Group

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Pl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 97
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 82C

Financial Performance

In 2025, NIOX Group's revenue was 48.70 million, an increase of 16.51% compared to the previous year's 41.80 million. Earnings were 7.00 million, an increase of 89.19%.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error